The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Valvular heart disease and/or dysfunction
Publications
Combined pergolide-associated valvular heart disease and achilles tendon contractures.
Acta medica academica 2012;41;228-30 — 2012 — 228-30
Valvular heart disease in patients exposed to pergolide: insights from the clinical presentation.
Pharmacoepidemiology and drug safety 2012 Mar;21;276-80 — 2012 Mar — 276-80
Valvular heart disease in patients with Parkinson's disease treated with pergolide, levodopa or both.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2009 Jan;16;83-7 — 2009 Jan — 83-7
Pergolide associated cardiac valvulopathy based on Ontario administrative data.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2008 May;35;173-8 — 2008 May — 173-8
Pergolide-associated valvular heart disease.
Comprehensive therapy 2006;32;94-101 — 2006 — 94-101
Valvular heart disease in patients taking pergolide.
Mayo Clinic proceedings 2005 Aug;80;1016-20 — 2005 Aug — 1016-20
The US Food and Drug Administration's registry of patients with pergolide-associated valvular heart disease.
Mayo Clinic proceedings 2003 Jun;78;730-1 — 2003 Jun — 730-1
Valvular heart disease in patients taking pergolide.
Mayo Clinic proceedings 2002 Dec;77;1280-6 — 2002 Dec — 1280-6